These outcomes imply that the course of treatment after postoperative relapse influences the OS of patients with EGFR-mutated NSCLC, though larger-scale prospective studies are needed to confirm these results in other clinical situations and patient cohorts. Here, EGFR is linked to non-small cell lung carcinoma.